MA27544A1 - CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES. - Google Patents

CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES.

Info

Publication number
MA27544A1
MA27544A1 MA27686A MA27686A MA27544A1 MA 27544 A1 MA27544 A1 MA 27544A1 MA 27686 A MA27686 A MA 27686A MA 27686 A MA27686 A MA 27686A MA 27544 A1 MA27544 A1 MA 27544A1
Authority
MA
Morocco
Prior art keywords
growth hormone
human growth
chemically modified
modified human
hormone conjugates
Prior art date
Application number
MA27686A
Other languages
French (fr)
Inventor
Rory F Finn
Ned R Siegel
Wei Liao
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MA27544A1 publication Critical patent/MA27544A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Conjugués de l'hormone de croissance humaine chimiquement modifiés La présente invention décrit une hormone de croissance humaine (hGH) modifiée chimiquement par liaison de la protéine avec un polymère soluble dans l'eau. La protéine modifiée au sens de l'invention, présente une activité hGH qui dure beaucoup plus longtemps que celle de l'hormone non modifiée, ce qui permet d'en réduire la dose et la fréquence d'administration.The present invention describes a chemically modified human growth hormone (hGH) by binding of the protein with a water-soluble polymer. The modified protein within the meaning of the invention has an hGH activity which lasts much longer than that of the unmodified hormone, which makes it possible to reduce the dose and the frequency of administration.

MA27686A 2001-11-20 2004-05-19 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES. MA27544A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
MA27544A1 true MA27544A1 (en) 2005-10-03

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27686A MA27544A1 (en) 2001-11-20 2004-05-19 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES.

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20070072924A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA008505B1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
PL397261A1 (en) * 2002-01-18 2012-03-26 Biogen Idec Ma Inc. Activated polyalkylene glycol polymer, composition and pharmaceutical composition and the use thereof
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
CA2498167C (en) 2002-09-09 2012-03-20 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
WO2005034988A1 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Long-acting molecules in sustained release formulations
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
ES2397241T3 (en) * 2004-01-21 2013-03-05 Novo Nordisk Health Care Ag Conjugation of peptides by transglutaminase
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
CA2590462C (en) * 2004-12-22 2017-02-28 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
CA2604222A1 (en) 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
CA2620638A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
NZ567234A (en) * 2005-11-08 2011-09-30 Ambrx Inc Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
CN101448512B (en) 2005-12-14 2015-11-25 Ambrx公司 Purposes containing alpha-non-natural amino acid and the compositions of polypeptide, the method relating to alpha-non-natural amino acid and polypeptide and alpha-non-natural amino acid and polypeptide
CA2655188A1 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
RU2488598C2 (en) * 2008-04-03 2013-07-27 Биостид Джене Експрешен Тек. Ко., Лтд. Double-stranded polyethylene glycol modified growth hormone, preparation method and use thereof
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same
WO2010014874A2 (en) * 2008-07-31 2010-02-04 Pharmaessentia Corp. Peptide-polymer conjugates
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
US8492503B2 (en) * 2008-09-11 2013-07-23 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds
CN102612376A (en) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 Growth hormones with prolonged in-vivo efficacy
ES2667025T3 (en) 2009-12-15 2018-05-09 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently bound to a polymer carrier
CA2787890C (en) 2010-01-22 2020-01-14 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
MX338357B (en) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
EP2571896A4 (en) * 2010-05-17 2014-01-08 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
CN105120887A (en) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 Growth hormone compound formulation
HUE064909T2 (en) 2014-11-06 2024-04-28 Pharmaessentia Corp Dosage regimen for pegylated interferon
PL3220892T3 (en) 2014-11-21 2022-01-31 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
WO2016145388A1 (en) * 2015-03-11 2016-09-15 Nektar Therapeutics Conjugates of an il-7 moiety and an polymer
EP3351561A4 (en) 2015-09-18 2019-05-15 University of Miyazaki Long-acting adrenomedullin derivative
CN114539384B (en) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
EP0458064B1 (en) * 1990-05-04 1998-02-25 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3628333B2 (en) * 1995-09-21 2005-03-09 ジェネンテック インコーポレーテッド Human growth hormone mutant
CN1269805A (en) * 1997-07-14 2000-10-11 博尔德生物技术公司 Derivatives of growth hormone and related proteins
NZ513077A (en) * 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
DK1157037T3 (en) * 1999-01-29 2003-11-24 Hoffmann La Roche G-CSF-conjugates
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
EP1352062A2 (en) * 2001-01-11 2003-10-15 Maxygen Aps Improved growth hormone molecules

Also Published As

Publication number Publication date
EA200700431A1 (en) 2008-02-28
OA13063A (en) 2006-11-10
CO5580794A2 (en) 2005-11-30
RS53104A (en) 2006-10-27
EA008505B1 (en) 2007-06-29
EA200400565A1 (en) 2005-06-30
KR20050044858A (en) 2005-05-13
MXPA04004809A (en) 2004-08-11
JP2006321808A (en) 2006-11-30
ZA200403907B (en) 2007-12-27
JP2005525302A (en) 2005-08-25
HRP20040448A2 (en) 2006-02-28
GEP20063860B (en) 2006-06-26
IL162031A0 (en) 2005-11-20
BR0214451A (en) 2006-05-30
TNSN04090A1 (en) 2006-06-01
NO20042182L (en) 2004-08-11
WO2003044056A2 (en) 2003-05-30
WO2003044056A3 (en) 2003-08-21
AP2004003050A0 (en) 2004-06-30
EP1453859A2 (en) 2004-09-08
AU2002356990A1 (en) 2003-06-10
KR20070072924A (en) 2007-07-06
CN1608079A (en) 2005-04-20
HUP0500997A2 (en) 2007-11-28
PL374354A1 (en) 2005-10-17
ECSP045114A (en) 2004-07-23
IS7268A (en) 2004-05-17
CA2467731A1 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
MA27544A1 (en) CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES.
DK1715887T3 (en) N-terminal Monopegylated Human Growth Hormone Conjugates, Methods for their Preparation and Use
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
WO1998051325A3 (en) Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
ATE383375T1 (en) WTI-MODIFIED PEPTIDE
EP2270148A3 (en) Method for controlling the activity of immunologically functional molecule
BR0212522A (en) Zinc binding ligand, insulin hexamer, aqueous insulin preparation and methods of prolonging the action of an insulin preparation and preparing a zinc binding ligand
NO20054440L (en) Liquid formulations of tumor necrosis factor binding proteins
ATE68976T1 (en) SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS.
SE8902638D0 (en) STABILIZED PROTEIN OR PEPTIDE CONJUGATES
EA199900979A1 (en) COMPOSITIONS OF ACTIVATED PROTEIN
DK1212422T3 (en) Human CTLA-4 antibodies and their uses
CY1108765T1 (en) ANTI-ErbB2 antibody treatment
BG104070A (en) Chimeric protein of interleukin-6, soluble receptor/ligand, its analogues and their application
EE200100507A (en) Hydroxymatairesinol for cancer prevention
IL205802A (en) Immunoconjugates comprising an immunoglobulin constant region and a biologically active molecule
PT1171465E (en) ANALYSIS OF A GASTRIC INHIBITOR AND THEIR USE FOR THE TREATMENT OF DIABETES
MXPA03007563A (en) Increased recovery of active proteins.
EA200000748A1 (en) METHOD OF INTRODUCTION OF MONOMERIAL INSULIN ANALOGUES
DK1146896T3 (en) Formulations containing monodisperse hexameric acylated insulin analogues
HK1023513A1 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
BR0316716A (en) Chemically Modified Human Growth Hormone Conjugates
EA200100905A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PROTONE PUMP INHIBITORS
DK0981362T3 (en) Use of GLP-2 agonists to improve the function of the upper gastrointestinal tract
WO2000006185A3 (en) Methods of using lanreotide, a somatostatin analogue